AstraZeneca and MRC form Landmark Collaboration
In an initiative that could signal a new era in private?public partnerships, AstraZeneca will make 22 compounds available for free to medical researchers next year for projects funded by the United Kingdom?s (UK) Medical Research Council (MRC).
In an initiative that could signal a new era in private–public partnerships, AstraZeneca will make 22 compounds available for free to medical researchers next year for projects funded by the United Kingdom’s (UK) Medical Research Council (MRC). The collaboration is yet another boost to UK research and acknowledges the long, complex, and expensive process of drug development by giving UK researchers access to compounds and funds that will allow studies to explore new treatment opportunities through better understanding of disease mechanisms. The MRC, which has fostered 29 Nobel Prize winners, has supported high-quality science for 100 years and is active several disease areas.
“Innovative collaborations are playing a crucial role in finding ways to unlock the potential of new treatments,” said David Brennan, AstraZeneca’s CEO, in a press release, “The UK has a strong heritage of research excellence in life sciences. We hope that in sharing these valuable clinical compounds with academic scientists through the MRC, new discoveries will be made by exploring additional uses of these compounds.”
As part of the collaboration, MRC is requesting research proposals from across the UK. A total of £10 million ($15.6 million) will be awarded to the projects judged to best use the AstraZeneca-developed compounds. Notably, these projects must not directly contribute to AstraZeneca’s active programs to secure the funding.
“The MRC is delighted to be partnering [with] AstraZeneca in this exciting new approach towards understanding disease mechanisms in humans and thereby speeding the development of new treatments,” said Sir John Savill, MRC’s chief executive, in the press release. “The initiative marks a new era in medical discovery, open innovation and public-private collaboration.”
Though IP generated will vary from project to project, AstraZeneca will retain rights over the chemical composition of the compounds, and academic institutions will own any new research findings. New research produced by the collaboration will be made available to the broader scientific community.
In an initiative that could signal a new era in private–public partnerships, AstraZeneca will make 22 compounds available for free to medical researchers next year for projects funded by the United Kingdom’s (UK) Medical Research Council (MRC). The collaboration is yet another boost to UK research and acknowledges the long, complex, and expensive process of drug development by giving UK researchers access to compounds and funds that will allow studies to explore new treatment opportunities through better understanding of disease mechanisms. The MRC, which has fostered 29 Nobel Prize winners, has supported high-quality science for 100 years and is active several disease areas.
“Innovative collaborations are playing a crucial role in finding ways to unlock the potential of new treatments,” said David Brennan, AstraZeneca’s CEO, in a press release, “The UK has a strong heritage of research excellence in life sciences. We hope that in sharing these valuable clinical compounds with academic scientists through the MRC, new discoveries will be made by exploring additional uses of these compounds.”
As part of the collaboration, MRC is requesting research proposals from across the UK. A total of £10 million ($15.6 million) will be awarded to the projects judged to best use the AstraZeneca-developed compounds. Notably, these projects must not directly contribute to AstraZeneca’s active programs to secure the funding.
“The MRC is delighted to be partnering [with] AstraZeneca in this exciting new approach towards understanding disease mechanisms in humans and thereby speeding the development of new treatments,” said Sir John Savill, MRC’s chief executive, in the press release. “The initiative marks a new era in medical discovery, open innovation and public-private collaboration.”
Though IP generated will vary from project to project, AstraZeneca will retain rights over the chemical composition of the compounds, and academic institutions will own any new research findings. New research produced by the collaboration will be made available to the broader scientific community.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Biophysical and Aggregate Characterization for the Development of Biologics
June 10th 2025This eBook explores how advanced particle analysis technologies are revolutionizing biologic drug development. It highlights the importance of accurately identifying and characterizing subvisible particles to ensure drug safety, stability, and regulatory compliance. Techniques like Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy (FMM) are often used for their capabilities in detecting protein aggregates and degraded excipients such as polysorbates. Case studies and experimental results demonstrate how these tools provide high-throughput, low-volume analysis that enhances decision-making in formulation screening and manufacturing.
Psilera, Hesperos Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
